Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-23-016273
Filing Date
2023-05-01
Accepted
2023-05-01 16:28:10
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A ntla_defa14a_2023.htm DEFA14A 18252
2 GRAPHIC img232108800_0.jpg GRAPHIC 1819160
3 GRAPHIC img232108800_1.jpg GRAPHIC 1263371
  Complete submission text file 0000950170-23-016273.txt   4264201
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37766 | Film No.: 23874127
SIC: 2835 In Vitro & In Vivo Diagnostic Substances